RxDoctor Payments Data

Janet Wright

Family · Sioux Falls, SDNPI 1649234105

Payments from drug & device makers

$1,768in general payments, 2019–2025

Across 85 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$435
  • AbbVie$329
  • Astellas Pharma US Inc$201
  • Pfizer$178
  • GSK$124
  • Novo Nordisk$119
  • plus $381 from 11 others

What the payments were for

  • Food & beverage$1,768100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,768 in reported general payments places this provider in the 85th percentile of 588 family providers in South Dakota.

See all family providers in South Dakota

Medicare billing

Part B allowed, 2024
$29,454
Medicare patients
259
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide33$49,043
OzempicSemaglutide35$40,226
EliquisApixaban18$21,539
JardianceEmpagliflozin21$16,963
RybelsusSemaglutide13$13,762
XareltoRivaroxaban11$13,538
JanuviaSitagliptin Phosphate17$12,454
Janumet XrSitagliptin Phos/Metformin Hcl12$12,292
Levothyroxine Sodium476$3,930
SynthroidLevothyroxine Sodium42$3,795
Rosuvastatin Calcium343$3,464
Losartan Potassium273$2,583
Duloxetine Hcl65$2,412
Omeprazole255$2,371
Escitalopram Oxalate147$2,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$119$53,98848 claims
Lilly USA, LLCMounjaro$42$49,04333 claims
PfizerEliquis$178$21,53918 claims
Boehringer IngelheimJardiance$21$16,96321 claims
AbbVieSynthroid$329$3,79542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 family providers in South Dakota.

Other family in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →